News ReleasesPrinter friendly version
Protox Efficacy Data to be Presented at Leading Cancer Research Conference
Thursday, April 14th, 2005 - Vancouver, British Columbia - Protox Therapeutics Inc.
('Protox' or the 'Company') announces that a paper describing the Company's
technology, has been selected for presentation at the 96th Meeting of the American
Association of Cancer Research (AACR), to be held in Anaheim, California (April 16-
20, 2005). This prestigious annual conference highlighting the latest developments
in cancer research is attended by over 25,000 delegates from universities, research
institutions and the pharmaceutical industry.
The paper, entitled Tumoricidal effects of a PSA activated pore forming toxin
summarizes studies conducted at Johns Hopkins Medicine under the direction of Dr.
Sam Denmeade. The data to be presented at the meeting will provide further
evidence of the efficacy of Protox Therapeutics' lead product, which is being
developed for the treatment of localized prostate cancer.
The paper was co-authored by Dr. Simon Williams, and Dr. Sam Denmeade, both of
John Hopkins Medicine and Dr. Tom Buckley, Protox' Chief Scientific Officer. Dr.
Williams was awarded the AACR-AFLAC Scholar in Training Award for this research.
He will present the paper on Wednesday, April 20.
Protox will issue a release on April 20 outlining some of the information to be
presented at the conference.
ABOUT PROTOX: Protox Therapeutics Inc. is developing novel cancer therapeutics
by engineering the naturally occurring bacterial toxin Aerolysin, which kills cells by
forming pores in them. The Company believes that its engineering approach will
produce targeted cancer therapeutics that have greater efficacy and fewer side
effects than existing cancer treatments.
For more information, contact: Terry Vanderkruyk Director, Investor Relations, Protox Therapeutics Inc. Tel: 604-688-4376 Cell: 604-789-0844 Fax: 604-688-0173
tvanderkruyk@protoxtherapeutics.com
|